Loss of the Y chromosome discovered as a new risk factor for heart disease

Men who lose their Y chromosome in part of their blood cells have an increased risk of cardiovascular disease

25-Feb-2025
Computer-generated image

Symbol image

With increasing age, men experience a so-called mosaic-like loss of the Y chromosome (LOY). The Y chromosome is not lost in all, but only in some of the white blood cells in particular - comparable to a mosaic of different cell types. Men over 60 are particularly affected. As blood cells are regularly renewed - white blood cells, for example, every few days to weeks - this loss can increase over time. This acquired genetic change goes unnoticed for a long time, but can affect cell function and increase the risk of certain diseases.

Higher risk of fatal heart attacks

A research team led by Prof. Andreas Zeiher from Goethe University and University Medicine Frankfurt investigated this connection in more detail. The scientists analyzed blood samples from almost 1,700 men who had taken part in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. This long-term study includes patient data from men who underwent cardiac catheterization between 1997 and 2000. The results are alarming: men with a pronounced Y chromosome loss not only had an overall higher risk of cardiovascular disease, but also a 50 percent higher probability of dying as a result of a heart attack.

The researchers discovered that blood cells without the Y chromosome release more messenger substances that promote inflammation and scarring in the heart tissue. Laboratory experiments have shown that this process alters the function of certain immune cells - with possible negative consequences for the heart.

New opportunities for targeted prevention

"Our results show that chromosomal changes that occur with age may play a greater role in heart health than we previously thought," says Prof. Andreas Zeiher. "In the long term, measuring Y chromosome loss could help to identify men with a particularly high risk at an early stage and treat them in a targeted manner."

These findings open up new possibilities for individually tailored prevention and treatment. In future, a simple blood test could help to identify high-risk patients at an early stage and provide targeted protection against cardiovascular disease.

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

Original publication

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Bruker announces acquisition of a spin-off from Ghent University - Acquisition expands nuclear molecular imaging portfolio

Researchers discover way to inhibit major cancer gene

Researchers discover way to inhibit major cancer gene

Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly - Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform

Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly - Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform

Medigenomix Acquires an Exclusive License for another Genetic Polymorphisms in G-Proteins for Applications in Pharmacogenetics

Breakthrough: Prospect of blood test for Parkinson’s disease for the first time - A new method reliably detects protein changes in blood that are typical of Parkinson's disease: "The results are really sensational"

Breakthrough: Prospect of blood test for Parkinson’s disease for the first time - A new method reliably detects protein changes in blood that are typical of Parkinson's disease: "The results are really sensational"

Evotec and Bayer partner to develop new treatments to fight kidney diseases

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

Vaccine-induced CD4 T cells have adverse effect in a mouse model of infection - Research offers a 'cautionary tale' for the development of CD4 T cell vaccines

Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b

Merck Plans to Invest € 1 Billion at the Darmstadt Site - Employment guarantee extended until the end of 2025

Merck Plans to Invest € 1 Billion at the Darmstadt Site - Employment guarantee extended until the end of 2025

Agilent Technologies Announces Winner of Third Annual Early Career Professor Award

Agilent Technologies Announces Winner of Third Annual Early Career Professor Award

Graham Nicholls Joins Almac as Director of Biostatistics